CA2130867C - An aerosol container and the use of an aerosol container - Google Patents
An aerosol container and the use of an aerosol container Download PDFInfo
- Publication number
- CA2130867C CA2130867C CA002130867A CA2130867A CA2130867C CA 2130867 C CA2130867 C CA 2130867C CA 002130867 A CA002130867 A CA 002130867A CA 2130867 A CA2130867 A CA 2130867A CA 2130867 C CA2130867 C CA 2130867C
- Authority
- CA
- Canada
- Prior art keywords
- container
- suspension
- metering chamber
- pharmaceutically active
- aerosol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/14—Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
- B65D83/44—Valves specially adapted therefor; Regulating devices
- B65D83/52—Valves specially adapted therefor; Regulating devices for metering
- B65D83/54—Metering valves ; Metering valve assemblies
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mechanical Engineering (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Nozzles (AREA)
- Details Of Rigid Or Semi-Rigid Containers (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention relates to an aerosol container for pharmaceutically active aerosols that are to be administered in predetermined amounts and that are supplied in the container in the form of a suspension, the suspension also comprising, in addition to a pharmaceutically active substance, at least a propellant gas. The aerosol container has a metering valve that comprises a metering chamber and a valve.stem. In a first position of the valve stem, the metering chamber is in communication with the interior of the container and has been filled with a predetermined amount of the aerosol. In a second position of the valve stem, the amount of aerosol disposed in the metering chamber is released. The propellant gas is an alternative propellant gas that is free of fluorochlorohydrocarbons, preferably a propellant gas that comprises only fluorohydrocarbons, and the inner wall of the container is coated with a plastics coating.
Description
z130ab'~
An aerosol container and the use of an aerosol container The invention relates to an aerosol container and to the use of an aerosol container in accordance with the respective independent patent claim.
Aerosols are today a common dosage form for pharmaceutically active substances. Many of those aerosols are to be administered in predetermined (metered) amounts.
For various reasons (for example stability), certain pharmaceutically active substances are supplied in the form of a suspension, that is to say the pharmaceutically active substance is present in the aerosol container, usually under pressure, in the form of small solids particles in a liquid, the liquid also comprising at least a propellant gas. That kind of formulation of pharmaceutically active substances has proved suitable for many substances, and especially also for corticosteroids.
In order to administer a predetermined amount of the pharmaceutically active substance, customary aerosol containers are provided with a metering valve having a metering chamber. In a first position of the valve, the metering chamber is in communication with the interior of the container and, in that position, has been filled with the predetermined amount of suspension. In a second position of the metering valve, the amount disposed in the metering chamber is then released in the form of an aerosol, since the liquid/solid mixture can expand. In that manner the aerosol can be administered, fox example orally or nasally, to the user.
Hitherto, the propellant gases used have been the widely known fluorochlorohydro-carbons. Those chlorinated propellant gases are now known to be harmful, since they destroy the ozone layer, and they therefore should, and must, be abolished and replaced by other propellant gases that do not damage the ozone layer. In some countries, very recently those propellant gases which comprise chlorinated hydrocarbons have even been banned by law.
So-called "alternative propellant gases" are therefore presented as an alternative, since they do not damage the ozone layer (ozone-depleting potential = 0). However, many pharmaceutical substances, when stored in the form of a suspension, are deposited on the inner wall of the container when those propellant gases are used, whereas that did not occur, or occurred only to a very small extent, when chlorinated hydrocarbons were used. Such deposits on the inner wall of the container may result in the desired amount of pharmaceutical active substance that is to be administered to the user not being present in the metering chamber. A further consequence is that the total amount of pharmaceutically active substance stored in the container cannot be administered, since a very considerable proportion of the total amount of pharmaceutically active substance introduced into the container remains deposited on (adheres to) the inner wall of the container.
The aim of the invention is therefore to provide a container in which the pharmaceutically active substance can be supplied in the formulation that has already proved suitable and in which, at the same time, it is possible for alternative propellant gases that do not damage the ozone layer to be used, without significant amounts of the pharmaceutically active substance being deposited on the inner wall of the container. In particular, that is to be possible for anti-asthmatically active pharmaceutical substances (for example cortico-steroids), but of course the intention is for it also to be possible for other classes of pharmaceutical substances to be stored in such containers without any significant deposits of active substance being deposited on the inner wall of the container.
The aim is achieved in accordance with the invention by a container in which the inner wall is coated with a plastic coating and in which the propellant gas is a propellant gas that is free of fluorochlorohydrocarbons, preferably a propellant gas that comprises only fluorohydrocarbons and, - 2a -where appropriate, also cosolvents and/or surfactants. With such an arrangement, on the one hand no or no significant ~ amounts of active substance are deposited on the inner wall of the container, and on the other hand the ozone layer is not damaged or destroyed. Especially advantageous materials that may be used for the plastics coating are, for example, polytetrafluoroethylene, widely known as Teflon, and also perfluoroethylenepropylene.
In accordance with this invention, there is provided an aerosol container system for metering and administering pharmaceutically active aerosols supplied in the form of a suspension, the suspension including a pharmaceutically active agent and a propellant gas free of fluorochlorohydrocarbons, said aerosol container system comprising: a container for storing the suspension comprising a container wall, the inner portion of said container wall which defines the interior of the container being coated with a plastics coating which inhibits the pharmaceutically active agent in the suspension from depositing thereon, and a metering valve system for dosing and releasing the suspension comprising a metering chamber and a valve stem, said valve stem capable of being displaced from a first position to a second position, wherein in the first position the valve stem affords communication between the interior of the container and the metering chamber while simultaneously blocking communication between the metering chamber and the outside of the aerosol container system such that the metering chamber can be filled with a dose of the suspension from the container, and wherein in the second position the valve stem blocks communication between the interior of the container and the metering chamber while simultaneously affording communication between the metering chamber and the outside of the aerosol container system such - 2b -that the dose of suspension in the metering chamber can be released from the aerosol container system.
In specific example embodiments of such containers, the thickness of the container wall may be in the range from approximately 0.1 mm to approximately 2 mm, and may be especially approximately 0.4 mm (depending on the material used), and the thickness of the plastics coating may be in the range from approximately 1 nm to approximately 1 mm, and may be especially some 10 nm. The wall thicknesses mentioned are customary for aerosol containers, so that the aerosol containers according to the invention, purely ~1~U~S0 externally and especially in respect of external dimensions, do not differ from customary containers and therefore, even if they have to be used to deliver the aerosol, for example, into an applicator for customary aerosol containers, their use poses no problem.
The volume of the interior of the container of such aerosols is in the 'range from approxim- , , ately 1 ml to approximately 100 ml and the volume of the metering chamber is~in the range from approximately 5 w1 to approximately 400 w1. Those volumes are customary, for example, when corticosteroids are used as the pharmaceutically active substance, for example for the corticosteroid with the chemical name "9«-chloro-6«-fluoro- 11 x,17«-dihydroxy-16«-methyl-3-oxo-androsta-1,4-diene-17~-methoxycarbonyl-17-propionate", but also for other pharmaceutically active and, especially, anti-asthmatically active substances, such as, for example; Formoterol, which may be in the form of its salt, Formoternl fumarate, the name of which according to IUPAC nomenclature is "(t)2'-hydroxy-5'-[(RS)-1-hydroxy-2-[[(RS)-p-methoxy-«-methylphenethyl]amino]ethyl]form-anilide ~ funaarate ~ dihydrate", or also for mixtures of Formoterol and the mentioned corticosteroid.
An especially suitable pharmaceutically active substance is the substance called "(1R,2S)-(3E,5~-7-[1-(3-trifluoromethylphenyl~l-hydroxy-10-(4-acetyl-3-hydroxy-pmpylphenoxy)-3,5-decadien-2-ylthio]-4-oxo-4H-1-benzopyrane-2-carboxylic acid"
or a sodium salt of that substance, since with those substances especially small deposits, or no deposits at all, occur on the inner wall of the container. The complete aerosol may there-fore in that case comprise 0.1 °Ro.to 296 of that active substance and HFA propellant gases (where appropriate, cosolvents and/or surfactants may also be included).
In the following, the invention is explained in detail with reference to the drawing. The single drawing is a diagrammatic representation in section of an example embodiment of an aerosol container according to the invention. The aerosol container is shown in the drawing in its "in use" position.
The aerosol container is indicated generally by the reference numeral 1. The inner wall of the container 1 is coated with a plastics coating 3, the importance of which will be dealt with in more detail further below. Mounted on the aerosol container 1 is a metering valve 2. The metering valve 2 comprises a valve stem 21, which is guided in a valve housing 25 and is displaceable against the force of a spring F in the valve housing 25.
Provided in the wall of the valve housing 25 are individual slots 26 which place the interior 10 of the ~~vVav~
An aerosol container and the use of an aerosol container The invention relates to an aerosol container and to the use of an aerosol container in accordance with the respective independent patent claim.
Aerosols are today a common dosage form for pharmaceutically active substances. Many of those aerosols are to be administered in predetermined (metered) amounts.
For various reasons (for example stability), certain pharmaceutically active substances are supplied in the form of a suspension, that is to say the pharmaceutically active substance is present in the aerosol container, usually under pressure, in the form of small solids particles in a liquid, the liquid also comprising at least a propellant gas. That kind of formulation of pharmaceutically active substances has proved suitable for many substances, and especially also for corticosteroids.
In order to administer a predetermined amount of the pharmaceutically active substance, customary aerosol containers are provided with a metering valve having a metering chamber. In a first position of the valve, the metering chamber is in communication with the interior of the container and, in that position, has been filled with the predetermined amount of suspension. In a second position of the metering valve, the amount disposed in the metering chamber is then released in the form of an aerosol, since the liquid/solid mixture can expand. In that manner the aerosol can be administered, fox example orally or nasally, to the user.
Hitherto, the propellant gases used have been the widely known fluorochlorohydro-carbons. Those chlorinated propellant gases are now known to be harmful, since they destroy the ozone layer, and they therefore should, and must, be abolished and replaced by other propellant gases that do not damage the ozone layer. In some countries, very recently those propellant gases which comprise chlorinated hydrocarbons have even been banned by law.
So-called "alternative propellant gases" are therefore presented as an alternative, since they do not damage the ozone layer (ozone-depleting potential = 0). However, many pharmaceutical substances, when stored in the form of a suspension, are deposited on the inner wall of the container when those propellant gases are used, whereas that did not occur, or occurred only to a very small extent, when chlorinated hydrocarbons were used. Such deposits on the inner wall of the container may result in the desired amount of pharmaceutical active substance that is to be administered to the user not being present in the metering chamber. A further consequence is that the total amount of pharmaceutically active substance stored in the container cannot be administered, since a very considerable proportion of the total amount of pharmaceutically active substance introduced into the container remains deposited on (adheres to) the inner wall of the container.
The aim of the invention is therefore to provide a container in which the pharmaceutically active substance can be supplied in the formulation that has already proved suitable and in which, at the same time, it is possible for alternative propellant gases that do not damage the ozone layer to be used, without significant amounts of the pharmaceutically active substance being deposited on the inner wall of the container. In particular, that is to be possible for anti-asthmatically active pharmaceutical substances (for example cortico-steroids), but of course the intention is for it also to be possible for other classes of pharmaceutical substances to be stored in such containers without any significant deposits of active substance being deposited on the inner wall of the container.
The aim is achieved in accordance with the invention by a container in which the inner wall is coated with a plastic coating and in which the propellant gas is a propellant gas that is free of fluorochlorohydrocarbons, preferably a propellant gas that comprises only fluorohydrocarbons and, - 2a -where appropriate, also cosolvents and/or surfactants. With such an arrangement, on the one hand no or no significant ~ amounts of active substance are deposited on the inner wall of the container, and on the other hand the ozone layer is not damaged or destroyed. Especially advantageous materials that may be used for the plastics coating are, for example, polytetrafluoroethylene, widely known as Teflon, and also perfluoroethylenepropylene.
In accordance with this invention, there is provided an aerosol container system for metering and administering pharmaceutically active aerosols supplied in the form of a suspension, the suspension including a pharmaceutically active agent and a propellant gas free of fluorochlorohydrocarbons, said aerosol container system comprising: a container for storing the suspension comprising a container wall, the inner portion of said container wall which defines the interior of the container being coated with a plastics coating which inhibits the pharmaceutically active agent in the suspension from depositing thereon, and a metering valve system for dosing and releasing the suspension comprising a metering chamber and a valve stem, said valve stem capable of being displaced from a first position to a second position, wherein in the first position the valve stem affords communication between the interior of the container and the metering chamber while simultaneously blocking communication between the metering chamber and the outside of the aerosol container system such that the metering chamber can be filled with a dose of the suspension from the container, and wherein in the second position the valve stem blocks communication between the interior of the container and the metering chamber while simultaneously affording communication between the metering chamber and the outside of the aerosol container system such - 2b -that the dose of suspension in the metering chamber can be released from the aerosol container system.
In specific example embodiments of such containers, the thickness of the container wall may be in the range from approximately 0.1 mm to approximately 2 mm, and may be especially approximately 0.4 mm (depending on the material used), and the thickness of the plastics coating may be in the range from approximately 1 nm to approximately 1 mm, and may be especially some 10 nm. The wall thicknesses mentioned are customary for aerosol containers, so that the aerosol containers according to the invention, purely ~1~U~S0 externally and especially in respect of external dimensions, do not differ from customary containers and therefore, even if they have to be used to deliver the aerosol, for example, into an applicator for customary aerosol containers, their use poses no problem.
The volume of the interior of the container of such aerosols is in the 'range from approxim- , , ately 1 ml to approximately 100 ml and the volume of the metering chamber is~in the range from approximately 5 w1 to approximately 400 w1. Those volumes are customary, for example, when corticosteroids are used as the pharmaceutically active substance, for example for the corticosteroid with the chemical name "9«-chloro-6«-fluoro- 11 x,17«-dihydroxy-16«-methyl-3-oxo-androsta-1,4-diene-17~-methoxycarbonyl-17-propionate", but also for other pharmaceutically active and, especially, anti-asthmatically active substances, such as, for example; Formoterol, which may be in the form of its salt, Formoternl fumarate, the name of which according to IUPAC nomenclature is "(t)2'-hydroxy-5'-[(RS)-1-hydroxy-2-[[(RS)-p-methoxy-«-methylphenethyl]amino]ethyl]form-anilide ~ funaarate ~ dihydrate", or also for mixtures of Formoterol and the mentioned corticosteroid.
An especially suitable pharmaceutically active substance is the substance called "(1R,2S)-(3E,5~-7-[1-(3-trifluoromethylphenyl~l-hydroxy-10-(4-acetyl-3-hydroxy-pmpylphenoxy)-3,5-decadien-2-ylthio]-4-oxo-4H-1-benzopyrane-2-carboxylic acid"
or a sodium salt of that substance, since with those substances especially small deposits, or no deposits at all, occur on the inner wall of the container. The complete aerosol may there-fore in that case comprise 0.1 °Ro.to 296 of that active substance and HFA propellant gases (where appropriate, cosolvents and/or surfactants may also be included).
In the following, the invention is explained in detail with reference to the drawing. The single drawing is a diagrammatic representation in section of an example embodiment of an aerosol container according to the invention. The aerosol container is shown in the drawing in its "in use" position.
The aerosol container is indicated generally by the reference numeral 1. The inner wall of the container 1 is coated with a plastics coating 3, the importance of which will be dealt with in more detail further below. Mounted on the aerosol container 1 is a metering valve 2. The metering valve 2 comprises a valve stem 21, which is guided in a valve housing 25 and is displaceable against the force of a spring F in the valve housing 25.
Provided in the wall of the valve housing 25 are individual slots 26 which place the interior 10 of the ~~vVav~
container 1 in communication with the interior 27 of the valve housing 25. The metering valve 2 also comprises a metering chamber 20, which is filled in a manner explained hereinafter through the slots 26 in the wall of the valve housing 25 with the aid of the valve stem 21. The interior 27 of the valve housing 25 is sealed from the metering chamber 20 by means of a seal 250; the metering chamber 20 is in turn sealed from the outside by a seal 251. Finally, the entire interior 10 of the container is in addition sealed from the outside by means of a seal 28 provided in the metering valve 2.
The stem 21 of the metering valve 2 has two channels 29 and 22. The channel 29 has at its "inner" end a transverse bore 24 which, in the illustrated first position of the stem 21, opens into the interior 27 of the valve housing 25 and thus places the interior 27 of the valve housing, and therefore the interior 10 of the container, in communication with the metering chamber 20. The volume of the metering chamber 20 determines the desired amount of aerosol that is to be administered. How that chamber is filled will be explained later. In any event, in that first position of the stem 21 no aerosol can escape from the metering chamber 20 to the outside, since the metering chamber 20 is sealed from the outside by the seal 251.
In the second position of the valve stem 21, the spring F is compressed and the stem 21 is pushed so far into the interior 27 of the valve housing 25 that there is no communication from the interior 27 of the valve housing 25 and from the interior 10 of the container 1 via the channel 29. In that second position of the stem 21, however, there is communication from the metering chamber 20 out to the user by means of a transverse bore 23 at the "inner" end of the channel 22. The amount of aerosol disposed in the metering chamber 20 can expand through that transverse bore 23 and the channel 22 and thus be administered to the user either directly or by means of a special applicator.
When the valve stem 21 is released again after the administration, the transverse bore 23 passes into the region of the seal 251, and the metering chamber 20 is sealed from the outside again. The stem 21 is at that point not yet back in its first end position, but the transverse bore 24 is already in communication with the interior 10 of the container 1, so that, as a result of the pressure difference (excess pressure in the container interior, dis-charged metering chamber), suspension immediately flows from the interior 10 of the container into the metering chamber 20 and fills that chamber. The metering chamber 20 is thus immediately refilled when the stem 21 is released or returned and the next admin-istration can therefore follow straightaway.
~1~U~6~1 .'.1:. ~.\:
The stem 21 of the metering valve 2 has two channels 29 and 22. The channel 29 has at its "inner" end a transverse bore 24 which, in the illustrated first position of the stem 21, opens into the interior 27 of the valve housing 25 and thus places the interior 27 of the valve housing, and therefore the interior 10 of the container, in communication with the metering chamber 20. The volume of the metering chamber 20 determines the desired amount of aerosol that is to be administered. How that chamber is filled will be explained later. In any event, in that first position of the stem 21 no aerosol can escape from the metering chamber 20 to the outside, since the metering chamber 20 is sealed from the outside by the seal 251.
In the second position of the valve stem 21, the spring F is compressed and the stem 21 is pushed so far into the interior 27 of the valve housing 25 that there is no communication from the interior 27 of the valve housing 25 and from the interior 10 of the container 1 via the channel 29. In that second position of the stem 21, however, there is communication from the metering chamber 20 out to the user by means of a transverse bore 23 at the "inner" end of the channel 22. The amount of aerosol disposed in the metering chamber 20 can expand through that transverse bore 23 and the channel 22 and thus be administered to the user either directly or by means of a special applicator.
When the valve stem 21 is released again after the administration, the transverse bore 23 passes into the region of the seal 251, and the metering chamber 20 is sealed from the outside again. The stem 21 is at that point not yet back in its first end position, but the transverse bore 24 is already in communication with the interior 10 of the container 1, so that, as a result of the pressure difference (excess pressure in the container interior, dis-charged metering chamber), suspension immediately flows from the interior 10 of the container into the metering chamber 20 and fills that chamber. The metering chamber 20 is thus immediately refilled when the stem 21 is released or returned and the next admin-istration can therefore follow straightaway.
~1~U~6~1 .'.1:. ~.\:
As has already been mentioned in the introduction, for various reasons (for example stability), many pharmaceutically active substances are supplied in the container under pressure in the form of a suspension, that is to say in the form of a liquid comprising the active substance in the fonm of solids particles. The liquid also comprises at least a pro-pellant gas so that, in the second position of the stem 21, the metered amount disposed in the metering chamber 20 can expand and can thus be administered to the user directly or by means of a special applicator, as has already been explained above.
Since the propellant gas comprises fluorohydrocarbons (preferably, for example, tetra-fluoroethane or heptafluoropropane) and is therefore not harmful to the ozone layer, the inner wall of the container 1 is coated with a plastics coating 3. That plastics coating 3 is preferably of polytetrafluoroethylene, also widely known by the name Teflon, or of per-fluoroethylenepropylene, or the layer is produced based on the particular plastics and applied. The use of those materials prevents significant deposits of the active substance on the inner wall of the container 1. The effects of corrosion and electrolysis between the container wall and the liquid or suspension are also avoided.
A wide variety of processes may be used to coat the inner wall of the container 1 with the plastics coating 3. For example, the coating process used may be plasma coating, an impregnating/spraying process, hard anodization with PTFE inclusion, chemical vapour deposition (CVD), physical vapour deposition (PVD) and other processes that are customary for that purpose. The use of plasma coating is especially preferred.
The container wall may be made, for example, from aluminium. The thickness of the wall is, for example, in the range from approximately 0.1 mm to approximaiely 2 mm and is preferably approximately 0.4 mm. The thickness of the plastics coating is in the range from approximately 1 nm to approximately 1 mm and is preferably approximately some nm to some 10 tun. Those wall thicknesses are typical of containers that have a total volume in the range from approximately 1 ml to approximately 100 ml and preferably from approximately 5 ml to approximately 20 ml. The metering volume, that is to say the volume of the metering chamber 20, is then, for example, in the range from approximately 5 w1 to approximately 400 t~l and is preferably from approximately 25 p.1 to approximately 200 w1.
The active substance to be administered may be, for example, an anti-asthmatically active substance or substance mixture, especially a substance or substance mixture from the corticosteroid or antiinflammatory steroid classes. Specifically, the corticosteroid may be .
the corticosteroid with the chemical name "9«-chloro-6a-fluoro-11~,17a-dihydroxy-16«-methyl-3-oxo-androsta-1,4-diene-17~-methoxycarbonyl-17-propionate".
Equally possible, however, is the administration of other pharmaceutically active and, especially, f anti-asthmatically active substances, such as ~-sympathomimetics, LTD4 antagonists, parasympatholytics, cromoglycinic acid, or of other active substances that are admin-istered via the lungs, nose or throat, as is the case with some proteins. It is furthermore also possible, for example, to store and administer in that manner Formoterol, for example in the form of its salt, Formoterol fumarate, the name of which according to IUPAC
nomenclature is "(t)2'-hydroxy-S'-[(RS)-1-hydroxy-2-[[(RS)-p-methoxy-«-methyl-phenethyl]amino]ethyl]formanilide ~ fumarate ~ dehydrate", or a mixture of Formoterol and the mentioned corticosteroid.
An especially suitable pharmaceutically active substance is also the substance called "(1R,2S)-(3E,5~-7-[1-(3-trifluoromethylphenyl)-1-hydroxy-10-(4-acetyl-3-hydroxy-2-propylphenoxy)-3,5-decadien-2-ylthio]-4-oxo-4H-1-benzopyrane-2-carboxylic acid", or a sodium salt of that substance, since with those substances especially small deposits, oa no deposits at all, occur on the inner wall of the container. The complete aerosol may therefore in that case comprise 0.1 % to 2 % of that active substance and HFA
propellant gases (where appropriate, cosolvents and/or surfactants may also be included).
Since the propellant gas comprises fluorohydrocarbons (preferably, for example, tetra-fluoroethane or heptafluoropropane) and is therefore not harmful to the ozone layer, the inner wall of the container 1 is coated with a plastics coating 3. That plastics coating 3 is preferably of polytetrafluoroethylene, also widely known by the name Teflon, or of per-fluoroethylenepropylene, or the layer is produced based on the particular plastics and applied. The use of those materials prevents significant deposits of the active substance on the inner wall of the container 1. The effects of corrosion and electrolysis between the container wall and the liquid or suspension are also avoided.
A wide variety of processes may be used to coat the inner wall of the container 1 with the plastics coating 3. For example, the coating process used may be plasma coating, an impregnating/spraying process, hard anodization with PTFE inclusion, chemical vapour deposition (CVD), physical vapour deposition (PVD) and other processes that are customary for that purpose. The use of plasma coating is especially preferred.
The container wall may be made, for example, from aluminium. The thickness of the wall is, for example, in the range from approximately 0.1 mm to approximaiely 2 mm and is preferably approximately 0.4 mm. The thickness of the plastics coating is in the range from approximately 1 nm to approximately 1 mm and is preferably approximately some nm to some 10 tun. Those wall thicknesses are typical of containers that have a total volume in the range from approximately 1 ml to approximately 100 ml and preferably from approximately 5 ml to approximately 20 ml. The metering volume, that is to say the volume of the metering chamber 20, is then, for example, in the range from approximately 5 w1 to approximately 400 t~l and is preferably from approximately 25 p.1 to approximately 200 w1.
The active substance to be administered may be, for example, an anti-asthmatically active substance or substance mixture, especially a substance or substance mixture from the corticosteroid or antiinflammatory steroid classes. Specifically, the corticosteroid may be .
the corticosteroid with the chemical name "9«-chloro-6a-fluoro-11~,17a-dihydroxy-16«-methyl-3-oxo-androsta-1,4-diene-17~-methoxycarbonyl-17-propionate".
Equally possible, however, is the administration of other pharmaceutically active and, especially, f anti-asthmatically active substances, such as ~-sympathomimetics, LTD4 antagonists, parasympatholytics, cromoglycinic acid, or of other active substances that are admin-istered via the lungs, nose or throat, as is the case with some proteins. It is furthermore also possible, for example, to store and administer in that manner Formoterol, for example in the form of its salt, Formoterol fumarate, the name of which according to IUPAC
nomenclature is "(t)2'-hydroxy-S'-[(RS)-1-hydroxy-2-[[(RS)-p-methoxy-«-methyl-phenethyl]amino]ethyl]formanilide ~ fumarate ~ dehydrate", or a mixture of Formoterol and the mentioned corticosteroid.
An especially suitable pharmaceutically active substance is also the substance called "(1R,2S)-(3E,5~-7-[1-(3-trifluoromethylphenyl)-1-hydroxy-10-(4-acetyl-3-hydroxy-2-propylphenoxy)-3,5-decadien-2-ylthio]-4-oxo-4H-1-benzopyrane-2-carboxylic acid", or a sodium salt of that substance, since with those substances especially small deposits, oa no deposits at all, occur on the inner wall of the container. The complete aerosol may therefore in that case comprise 0.1 % to 2 % of that active substance and HFA
propellant gases (where appropriate, cosolvents and/or surfactants may also be included).
Claims (9)
1. An aerosol container system for metering and administering pharmaceutically active aerosols supplied in the form of a suspension, the suspension including a pharmaceutically active agent and a propellant gas free of fluorochlorohydrocarbons, said aerosol container system comprising:
a container for storing the suspension comprising a container wall, the inner portion of said container wall which defines the interior of the container being coated with a plastics coating which inhibits the pharmaceutically active agent in the suspension from depositing thereon, and a metering valve system for dosing and releasing the suspension comprising a metering chamber and a valve stem, said valve stem capable of being displaced from a first position to a second position, wherein in the first position the valve stem affords communication between the interior of the container and the metering chamber while simultaneously blocking communication between the metering chamber and the outside of the aerosol container system such that the metering chamber can be filled with a dose of the suspension from the container, and wherein in the second position the valve stem blocks communication between the interior of the container and the metering chamber while simultaneously affording communication between the metering chamber and the outside of the aerosol container system such that the dose of suspension in the metering chamber can be released from the aerosol container system.
a container for storing the suspension comprising a container wall, the inner portion of said container wall which defines the interior of the container being coated with a plastics coating which inhibits the pharmaceutically active agent in the suspension from depositing thereon, and a metering valve system for dosing and releasing the suspension comprising a metering chamber and a valve stem, said valve stem capable of being displaced from a first position to a second position, wherein in the first position the valve stem affords communication between the interior of the container and the metering chamber while simultaneously blocking communication between the metering chamber and the outside of the aerosol container system such that the metering chamber can be filled with a dose of the suspension from the container, and wherein in the second position the valve stem blocks communication between the interior of the container and the metering chamber while simultaneously affording communication between the metering chamber and the outside of the aerosol container system such that the dose of suspension in the metering chamber can be released from the aerosol container system.
2. An aerosol container according to claim 1, wherein the plastics coating disposed on the inner wall of the container is of polytetrafluoroethylene or perfluoroethylenepropylene.
3. An aerosol container according to either claim 1 or claim 2, wherein the thickness of the container wall is in the range from 0.1 mm to 2 mm, and the thickness of the plastics coating is in the range from 1 nm to 1 mm.
4. An aerosol container according to any one of claims 1 to 3, wherein the volume of the interior of the container is in the range from 1 ml to 100 ml and the volume of the metering chamber is from 5 µl to 400 µl.
5. The use of an aerosol container according to any one of claims 1 to 4 for the storage and administration of a predetermined amount of a pharmaceutically active aerosol in the form of a suspension.
6. The use according to claim 5, wherein the pharmaceutically active substance in the suspension is an anti-asthmatically active substance or substance mixture.
7. The use according to claim 6, wherein the pharmaceutically active substance in the suspension is Formoterol or a corticosteroid.
8. The use according to claim 7 wherein the pharmaceutically active substance in the suspension is 9.alpha.-chloro-6.alpha.-fluoro-11.beta.,17.alpha.-dihydroxy-16.alpha.-methyl-3-oxo-androsta-1,4-diene-17.beta.-methoxycarbonyl-17-propionate, or a mixture thereof.
9. ~The use according to claim 6, wherein the pharmaceutically active substance is (1R,2S)-(3E,5Z)-7-[1-(3-trifluoromethylphenyl)-1-hydroxy-10-(4-acetyl-3-hydroxy-2-propylphenoxy)-3,5-decadien-2-ylthio]-4-oxo-4H-1-benzopyrane-2-carboxylic acid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93810614 | 1993-08-27 | ||
EP93810614.3 | 1993-08-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2130867A1 CA2130867A1 (en) | 1995-02-28 |
CA2130867C true CA2130867C (en) | 2006-07-11 |
Family
ID=8215022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002130867A Expired - Lifetime CA2130867C (en) | 1993-08-27 | 1994-08-25 | An aerosol container and the use of an aerosol container |
Country Status (11)
Country | Link |
---|---|
US (2) | US6596260B1 (en) |
EP (1) | EP0642992B1 (en) |
JP (1) | JP3610438B2 (en) |
AT (1) | ATE163623T1 (en) |
AU (1) | AU690913B2 (en) |
CA (1) | CA2130867C (en) |
DE (1) | DE59405357D1 (en) |
DK (1) | DK0642992T3 (en) |
ES (1) | ES2113074T3 (en) |
GR (1) | GR3026507T3 (en) |
HK (1) | HK1010716A1 (en) |
Families Citing this family (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596260B1 (en) * | 1993-08-27 | 2003-07-22 | Novartis Corporation | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
AU751859B2 (en) * | 1995-04-14 | 2002-08-29 | Smithkline Beecham Corporation | Metered dose inhaler for beclomethasone dipropionate |
ATE258813T1 (en) * | 1995-04-14 | 2004-02-15 | Smithkline Beecham Corp | DEVICE FOR THE DOSED INHALATION OF BECLOMETHASONE DIPROPRIONATE |
AU752682B2 (en) * | 1995-04-14 | 2002-09-26 | Smithkline Beecham Corporation | Metered dose inhaler for salmeterol |
CN1217654C (en) | 1995-04-14 | 2005-09-07 | 史密丝克莱恩比彻姆公司 | Metered dose inhaler for albuterol |
AU2002301285B2 (en) * | 1995-04-14 | 2005-09-08 | Smithkline Beecham Corporation | Metered dose inhaler for fluticasone propionate |
ATE297773T1 (en) | 1995-04-14 | 2005-07-15 | Smithkline Beecham Corp | DOSAGE INHALER FOR SALMETEROL |
CN1113675C (en) * | 1995-04-14 | 2003-07-09 | 葛兰素惠尔康公司 | Metered dose inhaler for fluticasone propionate |
EP0778001B1 (en) * | 1995-05-12 | 2004-04-07 | Seiko Epson Corporation | Apparatus for diagnosing condition of living organism and control unit |
FR2740527B1 (en) * | 1995-10-31 | 1998-01-02 | Valois | LOW FRICTION VALVE ROD |
US5871010A (en) * | 1996-06-10 | 1999-02-16 | Sarnoff Corporation | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
GB9626960D0 (en) * | 1996-12-27 | 1997-02-12 | Glaxo Group Ltd | Valve for aerosol container |
US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
GB2329939A (en) | 1997-06-26 | 1999-04-07 | Glaxo Group Ltd | Self-lubricating valve stem for aerosol containers |
GB2322847A (en) * | 1997-11-05 | 1998-09-09 | Bespak Plc | Metering valve |
DK1066073T4 (en) † | 1998-02-23 | 2008-06-16 | Glaxo Group Ltd | dispensing containers |
GB9814717D0 (en) * | 1998-02-23 | 1998-09-02 | Bespak Plc | Improvements in drug delivery devices |
GB9805938D0 (en) * | 1998-03-19 | 1998-05-13 | Glaxo Group Ltd | Valve for aerosol container |
DZ2947A1 (en) | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Pressure metered dose inhaler. |
GB9904919D0 (en) | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
US6315985B1 (en) | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
IT1313553B1 (en) | 1999-07-23 | 2002-09-09 | Chiesi Farma Spa | OPTIMIZED FORMULATIONS CONSTITUTED BY SOLUTIONS OF STEROIDS GIVEN BY INHALATION. |
GB9918627D0 (en) | 1999-08-07 | 1999-10-13 | Glaxo Group Ltd | Valve |
FR2798367B1 (en) * | 1999-09-15 | 2001-11-23 | Valois Sa | VALVE GASKET FOR DOSING VALVE |
IL150397A0 (en) * | 2000-01-14 | 2002-12-01 | Astrazeneca Ab | A method for applying a polymer coating to the internal surface of a container |
DE10004465A1 (en) * | 2000-02-02 | 2001-08-16 | Pari Gmbh | Inhalation nebulizer, comprises a liquid reservoir with an artificial surface structure comprising protrusions and indentations |
IT1317846B1 (en) | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | FORMULATIONS CONTAINING AN ANTICOLINERGIC DRUG FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE BRONCOPNEUMOPATHY. |
US20030183223A1 (en) * | 2000-03-01 | 2003-10-02 | Hailey Andrew Mark | Metered dose inhaler |
JP2003525099A (en) | 2000-03-01 | 2003-08-26 | グラクソ グループ リミテッド | Metered dose inhaler |
AU2000250701B2 (en) | 2000-05-22 | 2004-07-01 | Chiesi Farmaceutici S.P.A. | Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
TW523409B (en) | 2000-09-15 | 2003-03-11 | Baxter Int | Container for inhalation anesthetic |
US20030207057A1 (en) * | 2000-09-18 | 2003-11-06 | Britto Ignatius Loy | Metered dose inhaler can coated two or more times with fluorocarbon polymers |
GB0025092D0 (en) * | 2000-10-13 | 2000-11-29 | Glaxo Group Ltd | Medicament dispenser |
SE0004610D0 (en) | 2000-12-13 | 2000-12-13 | Astrazeneca Ab | Surface modification process |
NZ526564A (en) * | 2000-12-22 | 2004-12-24 | Glaxo Group Ltd | Metered dose inhaler for salmeterol xinafoate |
GB0106046D0 (en) * | 2001-03-12 | 2001-05-02 | Glaxo Group Ltd | Canister |
SI1273292T1 (en) | 2001-07-02 | 2004-12-31 | Chiesi Farmaceutici S.P.A. | Optimised formulation of tobramycin for aerosolization |
JP2005504090A (en) | 2001-09-26 | 2005-02-10 | バクスター・インターナショナル・インコーポレイテッド | Preparation of submicron size-nanoparticles by removal of dispersion and solvent or liquid phase |
GB0125380D0 (en) * | 2001-10-23 | 2001-12-12 | Glaxo Group Ltd | Medicament dispenser |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
CA2502986C (en) | 2002-10-25 | 2011-08-23 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
FR2856990A1 (en) * | 2003-07-02 | 2005-01-07 | Valois Sas | Fluid product e.g. aerosol, distributing valve e.g. dosing valve, has valve stem with dosing chamber sealed from container and outside, in rest position of valve, and two valves activated together for filling container |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
EP1595531A1 (en) | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
GB0405634D0 (en) * | 2004-03-12 | 2004-04-21 | Univ Southampton | Anti-virus therapy for respiratory diseases |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
GB0425518D0 (en) | 2004-11-19 | 2004-12-22 | Clinical Designs Ltd | Substance source |
CA2590839A1 (en) * | 2004-12-15 | 2006-06-22 | 3M Innovative Properties Company | Elastomer seals for use in medicinal aerosol devices |
GB0428204D0 (en) * | 2004-12-23 | 2005-01-26 | Clinical Designs Ltd | Medicament container |
US20070069046A1 (en) * | 2005-04-19 | 2007-03-29 | Foamix Ltd. | Apparatus and method for releasing a measure of content from a plurality of containers |
FR2885889B1 (en) * | 2005-05-20 | 2007-10-19 | Valois Sas | FLUID PRODUCT DELIVERY VALVE |
AU2006277929B2 (en) * | 2005-08-08 | 2010-07-15 | Novartis Ag | Insulated canister for metered dose inhalers |
US8367734B1 (en) | 2005-08-11 | 2013-02-05 | Amphastar Pharmaceuticals Inc. | Stable epinephrine suspension formulation with high inhalation delivery efficiency |
US20070272768A1 (en) * | 2006-05-26 | 2007-11-29 | Williams Donald R | Water-Based Airless Adhesive Application Container |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US8722736B2 (en) | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
WO2009056991A2 (en) * | 2007-09-04 | 2009-05-07 | Foamix Ltd. | Device for delivery of a foamable composition |
GB0721737D0 (en) * | 2007-11-06 | 2007-12-19 | 3M Innovative Properties Co | Medicinal inhalation devices and components thereof |
AU2008323924B2 (en) * | 2007-11-06 | 2013-01-17 | 3M Innovative Properties Company | Medicinal inhalation devices and components thereof |
GB0721739D0 (en) * | 2007-11-06 | 2007-12-19 | 3M Innovative Properties Co | medicinal inhalation devices and components thereof |
US20090130046A1 (en) * | 2007-11-20 | 2009-05-21 | S.C Johnson & Son, Inc. | Concentrated Fragrance Composition Provided in Metered Aerosol Spray |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
US8227027B2 (en) * | 2007-12-07 | 2012-07-24 | Presspart Gmbh & Co. Kg | Method for applying a polymer coating to an internal surface of a container |
WO2009090495A2 (en) | 2007-12-07 | 2009-07-23 | Foamix Ltd. | Oil and liquid silicone foamable carriers and formulations |
EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
WO2009087224A1 (en) | 2008-01-11 | 2009-07-16 | Novartis Ag | Pyrimidines as kinase inhibitors |
WO2009090558A2 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
GB0904059D0 (en) | 2009-03-10 | 2009-04-22 | Euro Celtique Sa | Counter |
GB0904040D0 (en) | 2009-03-10 | 2009-04-22 | Euro Celtique Sa | Counter |
EP2236227B1 (en) | 2009-03-30 | 2013-12-18 | Boehringer Ingelheim International GmbH | Forming tool with a rotatable base body |
EP2236224B1 (en) * | 2009-03-30 | 2013-03-06 | Boehringer Ingelheim International GmbH | Forming tool with a rotatable basis body for forming an inhalator cartridge and use of such a tool |
EP2662472B1 (en) | 2009-03-31 | 2019-02-27 | Boehringer Ingelheim International Gmbh | Method for coating a surface of a component |
CA2662490C (en) * | 2009-04-15 | 2016-07-19 | Klenzoid Company Limited | Polymer delivery system and method for waste water facility |
CA2760186C (en) | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US20120097159A1 (en) | 2009-05-06 | 2012-04-26 | Suresh Iyer | Medicinal inhalation devices and components thereof |
US9278048B2 (en) * | 2009-05-06 | 2016-03-08 | Baxter International, Inc. | Pharmaceutical product and method of use |
CN102460635B (en) | 2009-05-06 | 2014-12-24 | 3M创新有限公司 | Apparatus and method for plasma treatment of containers |
US8815325B2 (en) | 2009-05-06 | 2014-08-26 | 3M Innovative Properties Company | Medicinal inhalation device |
US9265910B2 (en) | 2009-05-18 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Adapter, inhalation device, and nebulizer |
DE102009022318A1 (en) * | 2009-05-22 | 2010-12-23 | Schott Solar Ag | Method for producing a photovoltaic module |
EP2457181A4 (en) | 2009-07-24 | 2013-01-23 | Digimarc Corp | Improved audio/video methods and systems |
CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
MX359879B (en) | 2009-10-02 | 2018-10-12 | Foamix Pharmaceuticals Ltd | Topical tetracycline compositions. |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
GB0918149D0 (en) | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
GB0918150D0 (en) | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved formulations |
JP5658268B2 (en) | 2009-11-25 | 2015-01-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Nebulizer |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
EP2504052B1 (en) | 2009-11-25 | 2022-07-27 | Boehringer Ingelheim International GmbH | Nebulizer |
GB201003273D0 (en) | 2010-02-26 | 2010-04-14 | Portal Medical Ltd | Medicament dispenser device |
GB201003275D0 (en) | 2010-02-26 | 2010-04-14 | Portal Medical Ltd | Method of manufacturing a medicament dispenser device |
EP2585151B1 (en) | 2010-06-24 | 2018-04-04 | Boehringer Ingelheim International GmbH | Nebulizer |
FR2961795A1 (en) | 2010-06-28 | 2011-12-30 | Lindal France Sas | DOSING VALVE FOR PRESSURIZED BOTTLE |
WO2012007843A2 (en) | 2010-07-12 | 2012-01-19 | Foamix Ltd. | Apparatus and method for releasing a unit dose of content from a container |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
SG10201510159XA (en) * | 2010-12-10 | 2016-01-28 | Advanced Tech Materials | Generally cylindrically-shaped liner for use in pressure dispense systems and methods of manufacturing the same |
EP2694220B1 (en) | 2011-04-01 | 2020-05-06 | Boehringer Ingelheim International GmbH | Medical device comprising a container |
US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
US20120318827A1 (en) * | 2011-06-15 | 2012-12-20 | Steven Schennum | Canister |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
WO2013152894A1 (en) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Atomiser with coding means |
US20140171404A1 (en) | 2012-12-19 | 2014-06-19 | Novartis Ag | Autotaxin inhibitors |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
BR112016000779A8 (en) | 2013-07-18 | 2020-01-07 | Novartis Ag | autotaxin inhibitors that comprise heteroaromatic ring benzylamide cycle nucleus, their uses, pharmaceutical composition and combination |
WO2015008229A1 (en) | 2013-07-18 | 2015-01-22 | Novartis Ag | Autotaxin inhibitors |
ES2836977T3 (en) | 2013-08-09 | 2021-06-28 | Boehringer Ingelheim Int | Nebulizer |
EP3030298B1 (en) | 2013-08-09 | 2017-10-11 | Boehringer Ingelheim International GmbH | Nebulizer |
WO2015162558A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Autotaxin inhibitors |
ES2667424T3 (en) | 2014-04-24 | 2018-05-10 | Novartis Ag | Pyrazine derivatives as phosphatidyl-inositol-3-kinase inhibitors |
US10112926B2 (en) | 2014-04-24 | 2018-10-30 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
BR112016024533A8 (en) | 2014-04-24 | 2021-03-30 | Novartis Ag | amino pyrazine derivatives as phosphatidylinositol 3-kinase or salt inhibitors, their use, and pharmaceutical composition and combination |
ES2954961T3 (en) | 2014-05-07 | 2023-11-27 | Boehringer Ingelheim Int | Unit, nebulizer and method |
DK3139984T3 (en) | 2014-05-07 | 2021-07-19 | Boehringer Ingelheim Int | Atomizer |
RS64124B1 (en) | 2014-05-07 | 2023-05-31 | Boehringer Ingelheim Int | Nebulizer and container |
US20170088545A1 (en) | 2014-05-14 | 2017-03-30 | Novartis Ag | Carboxamide inhibitors |
WO2015173659A2 (en) | 2014-05-14 | 2015-11-19 | Novartis Ag | Carboxamide derivatives |
FR3049275B1 (en) * | 2016-03-23 | 2019-07-19 | Aptar France Sas | DOSING VALVE AND DEVICE FOR DISPENSING FLUID PRODUCT COMPRISING SUCH A VALVE |
MX2020012139A (en) | 2016-09-08 | 2021-01-29 | Vyne Pharmaceuticals Inc | Compositions and methods for treating rosacea and acne. |
DE112017007053T5 (en) | 2017-02-14 | 2019-10-31 | Presspart Gmbh & Co. Kg | Method for sealingly connecting a canister and a top cover |
FR3065891B1 (en) * | 2017-05-05 | 2021-12-24 | Aptar France Sas | METERING VALVE AND FLUID PRODUCT DISTRIBUTION DEVICE COMPRISING SUCH A VALVE. |
GB201717996D0 (en) * | 2017-10-31 | 2017-12-13 | Portal Medical Ltd | Medicament dispenser device |
EP3756711A1 (en) | 2019-06-25 | 2020-12-30 | Presspart Gmbh & Co. Kg | Method of plasma cleaning and coating of mdi cans |
CN113038982A (en) * | 2019-07-29 | 2021-06-25 | 上海谷森医药有限公司 | Cartridge for aerosol inhalation with single-layer container and nozzle-shaped cap |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2815889A (en) | 1955-07-28 | 1957-12-10 | Engine Parts Mfg Company | Metering device controlling discharge of fluids from aerosol containers |
US2886217A (en) | 1957-05-20 | 1959-05-12 | Riker Laboratories Inc | Dispensing device |
US3324069A (en) * | 1964-10-23 | 1967-06-06 | Pennsalt Chemicals Corp | Vinylidene fluoride polymer dispersions |
GB1064840A (en) | 1964-11-23 | 1967-04-12 | Du Pont | Tetrafluoroethylene/hexafluoropropylene copolymer dispersions |
DE1226251B (en) | 1965-07-10 | 1966-10-06 | Siegfried Witte | Use of plastic for making or lining vessels for liquid metal or alloys |
FR1584784A (en) * | 1968-08-13 | 1970-01-02 | ||
GB1415778A (en) | 1973-04-16 | 1975-11-26 | Ici Ltd | Increasing the molecular weight of aromatic polysulphones |
JPS515447B2 (en) | 1971-08-31 | 1976-02-20 | ||
NL167983C (en) * | 1973-11-19 | 1982-02-16 | Ici Ltd | PROCESS FOR THE PREPARATION OF A COATING MATERIAL AND ITS COATED ARTICLES THEREOF. |
FR2267496A1 (en) | 1974-04-11 | 1975-11-07 | Sidel Sa | Method of sealing valve on aerosol container - uses internally ribbed sleeve over ribbed valve and sleeve |
CH628355A5 (en) | 1976-02-24 | 1982-02-26 | Ciba Geigy Ag | METHOD FOR PRODUCING NEW ANDROSTADIEN-17BETA-CARBONIC ACIDS AND THEIR ESTERS AND SALTS. |
GB2077229B (en) | 1980-05-16 | 1983-08-03 | Neotechnic Eng Ltd | Valve assembly for a pressurized aerosoldispensing container |
JPH0335399Y2 (en) | 1985-11-08 | 1991-07-26 | ||
DE68915203T2 (en) | 1988-03-22 | 1994-09-22 | Fisons Plc | Pharmaceutical blends. |
FI94342C (en) * | 1988-03-29 | 1995-08-25 | Ciba Geigy Ag | Process for the preparation of new alkanophenones |
US5149717A (en) | 1988-03-29 | 1992-09-22 | Ciba-Geigy Corporation | Alkanophenones useful for treating allergies |
US4902318A (en) | 1988-05-25 | 1990-02-20 | The United States Of America As Represented By The Administrator Of The Environmental Protection Agency | Inlet apparatus for gas-aerosol sampling |
JP2517748B2 (en) | 1988-07-12 | 1996-07-24 | 株式会社大阪造船所 | Air can |
US5290539A (en) | 1990-12-21 | 1994-03-01 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
US5349947A (en) * | 1993-07-15 | 1994-09-27 | Newhouse Michael T | Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow |
US6596260B1 (en) * | 1993-08-27 | 2003-07-22 | Novartis Corporation | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
US7341345B2 (en) | 2004-07-19 | 2008-03-11 | Massachusetts Eye & Ear Infirmary | Ocular wavefront-correction profiling |
JP4736867B2 (en) | 2006-03-07 | 2011-07-27 | オイレス工業株式会社 | Cylindrical cylindrical bearing bush, manufacturing method thereof, and hinge structure using the cylindrical cylindrical bushing |
JP4833021B2 (en) | 2006-10-26 | 2011-12-07 | 株式会社フジクラ | Waveform display device, waveform display method, and waveform display program |
-
1994
- 1994-08-10 US US08/288,415 patent/US6596260B1/en not_active Expired - Lifetime
- 1994-08-18 AT AT94810478T patent/ATE163623T1/en active
- 1994-08-18 ES ES94810478T patent/ES2113074T3/en not_active Expired - Lifetime
- 1994-08-18 EP EP94810478A patent/EP0642992B1/en not_active Expired - Lifetime
- 1994-08-18 DK DK94810478T patent/DK0642992T3/en active
- 1994-08-18 DE DE59405357T patent/DE59405357D1/en not_active Expired - Lifetime
- 1994-08-23 AU AU71429/94A patent/AU690913B2/en not_active Expired
- 1994-08-25 CA CA002130867A patent/CA2130867C/en not_active Expired - Lifetime
- 1994-08-29 JP JP22734194A patent/JP3610438B2/en not_active Expired - Lifetime
-
1998
- 1998-04-03 GR GR980400690T patent/GR3026507T3/en unknown
- 1998-10-30 HK HK98111659A patent/HK1010716A1/en not_active IP Right Cessation
-
2003
- 2003-04-28 US US10/424,633 patent/US8119105B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2130867A1 (en) | 1995-02-28 |
ES2113074T3 (en) | 1998-04-16 |
AU7142994A (en) | 1995-03-09 |
GR3026507T3 (en) | 1998-07-31 |
EP0642992B1 (en) | 1998-03-04 |
US20030194379A1 (en) | 2003-10-16 |
DK0642992T3 (en) | 1998-12-07 |
US6596260B1 (en) | 2003-07-22 |
HK1010716A1 (en) | 1999-06-25 |
JPH0776380A (en) | 1995-03-20 |
ATE163623T1 (en) | 1998-03-15 |
US8119105B2 (en) | 2012-02-21 |
EP0642992A2 (en) | 1995-03-15 |
DE59405357D1 (en) | 1998-04-09 |
AU690913B2 (en) | 1998-05-07 |
JP3610438B2 (en) | 2005-01-12 |
EP0642992A3 (en) | 1995-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2130867C (en) | An aerosol container and the use of an aerosol container | |
US7793655B2 (en) | Two-chamber cartridge for propellant-free metering aerosols | |
US4667668A (en) | Dosage inhalator | |
US6610273B2 (en) | Process for making chemically stable C-17/21 OH 20-ketosteroid aerosol products | |
US7735696B2 (en) | Metering valve | |
MA26763A1 (en) | PHARMACEUTICAL COMPOSITION OF AEROSOLS CONTAINING HFA 237 & HFA 134A | |
CA2215255A1 (en) | Butixocort aerosol formulations | |
CZ412499A3 (en) | Aerosol therapeutical preparations | |
AU2012322453B2 (en) | Compositions comprising salbutamol sulphate | |
JPH09500855A (en) | Seals for use in aerosol delivery devices | |
KR19980703849A (en) | Metering Inhaler for Fluticasone Propionate | |
SK9482002A3 (en) | A device for delivering metered aerosols | |
CA2437746A1 (en) | Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein | |
CA2329900A1 (en) | Metered-dose valve for pharmaceutical aerosol | |
SK16062002A3 (en) | Pharmaceutical formulation for administration through pressurized metered dose inhalers and method for preparation thereof | |
US20230233777A1 (en) | Carbon dioxide based metered dose inhaler | |
GB2467758A (en) | Metered dose inhaler with internal coating of siloxane and/or silazane | |
GB2401099A (en) | Improvements in valves for pressurised dispensing containers | |
GB2464943A (en) | A valve stem for a metering valve |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20140825 |